Summary The Y haptenic blood group determinant is expressed on the cells of malignant gastrointestinal tumours and on the normal gastrointestinal epithelium of individuals who can secrete blood group antigens. An enzyme-linked immunosorbent assay incorporating the high affinity biotin-avidin interaction was developed to measure the serum levels of antigens bearing the Y hapten in patients with colorectal cancer. The specificity of the assays was between 88 and 93% and the sensitivity in detecting extensive disease was between 24 and 34%. However, up to 67% of patients with local or abdominal recurrent disease secreted antigens expressing the Y hapten, whereas only 30% of patients with overt hepatic metastases secreted a similar antigen. Recognition of antigens bearing the Y hapten may therefore be useful in detecting early local relapse of colorectal cancer when a second operation to excise the recurrence may be possible.
There is considerable interest in non-invasive techniques for the identification of patients with recurrent disease or liver metastases following resection of primary colorectal tumours. At present carcinoembyronic antigen (CEA) is used in postoperative monitoring, in an attempt to detect early relapse. However, Finlay and McArdle (1983) showed recurrence to be identified by computerised tomography 7.5 months before any increase in CEA was seen. There is an urgent requirement for detection of a new tumour associated antigen which is secreted by a large percentage of early recurrent tumours, or for identification of an antigen which would complement CEA monitoring of recurrent disease.
The difucosylated type 2 carbohydrate chain associated with the H blood group antigen is referred to as the Y hapten. The monoclonal antibody C14, raised against extranuclear membranes of a human colonic adenoma has been shown to define the Y hapten (Brown et al., 1983) . Using C14, Brown et al. (1984) showed that 96% of colorectal adenocarcinomas and 100% of adenomas expressed the Y hapten. The expression was greater than that shown by any normal colonic mucosa (Durrant et al., 1986) . Although Y hapten can be detected in saliva from individuals who are blood group secretors, it is not known whether antigens bearing the Y hapten are shed into the circulation. We have developed a rapid accurate enzyme-linked immunosorbent assay to screen for antigen bearing Y hapten in sera.
Materials and methods
Monoclonal antibody C14 is an IgM monoclonal antibody which was purified from mouse ascitic fluid on lentil lectin sepharose as previously described (Takacs & Staehelin, 1981) and stored at a concentration of 3.07 mg ml-' at -70°C. NCRC-21 is an IgM monoclonal antibody which was raised against a colorectal tumour glycolipid extract. It was subsequently found to react with an epitope on a high molecular weight mucin which also expressed the Y hapten (M.R. Price, unpublished results). It was purified from mouse ascitic fluid on lentil lectin sepharose as described above.
Immunoflourescence
The activity of the biotinylated C14 was tested by indirect immunofluorescence on the colorectal cell line C170. Briefly, 2 x 106 cells were incubated at 4°C for 30 min with antibody (10 gg) before washing and incubating with either FITCrabbit anti-mouse immunoglobulins (Dakopatts, Denmark) or FITC streptavidin (Serotech, Bicester, UK). Both incubations were for 30 min at 4°C. The cells were washed before analysis on a FACS IV using similar conditions to those previously described (Durrant el al., 1986) .
Biotinylation of C14 Incubation of C14 monoclonal antibody with varying concentrations (30-120 Ig ml-') of N-hydroxysuccinamide (NHS)-biotin (Guesden et al., 1979) for I h at 4°C in the dark resulted in complete loss of antigen-antibody binding (Table I) .
Conjugation of certain macromolecules to NHS-biotin may cause steric hindrance of the biotin-avidin interaction. The use of a spacer arm limits this problem. C14 was therefore labelled using a long chain derivative of NHS-biotin with a 13 atom spacer, arm, sulphosuccinimidyl-6-(biotin amindo)hexanote (NHS-LC-biotin; Pierce, Illinois, USA).
Freshly prepared NHS-LC biotin was dissolved in dimethylformamide (2 mg ml') and added gg per I mg of antibody) to C14 monoclonal antibody in sodium bicarbonate buffer at pH 9.0. The reaction was stirred gently in the dark for I h. Biotinylated antibody was separated from free NHS-LC-biotin on a PD-10 column, when NHS-LC- biotin was used at concentration of 60 lag ml-' it resulted in retention of antibody binding (Table I ) and good levels of biotinylation (Table I ). The lower mean fluorescence obtained using streptavidin-FITC compared to rabbit antimouse-FITC were due to differing binding ratios. Each biotin molecule can bind only one streptavidin FITC whereas each mouse antibody can bind two to three rabbit anti-mouse antibodies. There are two to three molecules of fluorescein secretors confirmed that antigens bearing two Y haptens or an NCRC-21 epitope and a Y hapten existed (Figure 1) . However, when the serum from normal individuals was screened (Figure 1 ), sera from 3/43 (7%) normal donors gave a positive result with the C14 capturing antibody (Figure 1 ). Only one of these positive sera was from an individual with antigen in his saliva. Sera from 34% of the patients with colorectal cancer gave positive results when C14 was the capturing antibody ( Figure  2 ). However, 67% of the patients with pelvic or abdominal recurrent disease secreted antigen bearing the Y hapten into their serum compared with 30% of patients with metastases were positive (X2 = 4.6;0.05>P>0.02). Five patients had both liver metastases and recurrent disease. Of these three showed positive results and two were negative. If these patients are excluded from the total patient analysis 70% of patients with only recurrent disease and 28% of patients with metastases alone are positive. Antigen captured by NCRC-21 monoclonal antibody was detected in 24% of patients sera. Thirty-three per cent of patients with recurrent disease expressed this antigen and 22% of patients with metastases ( Figure 2 ).
There was no correlation between expression of the antigen(s) captured by C14 and those captured by NCRC-21 (Figure 3) . Seven patients secreted an antigen expressing two Y haptenic determinants but no NCRC-21 defined antigen whereas one patient expressed the NCRC-21 defined antigen but did not express two accessible Y haptenic determinants. Furthermore, there was no correlation between the expression of CEA, CAI 9-9 and the two types of antigen defined in these assays (Figure 3) . A disease as 73% of these patients had elevated levels of this antigen. The sensitivity of detection of recurrent disease is similar for CEA and C14 assays. However, detection of both recurrence and metastatic disease can be increased to 80% and 82%, if CEA assays are combined with C14 and NCRC-21 ELISAs. Similarly, the sensitivity of the CA19-9 assay in detecting recurrent disease can be doubled by also screening by C14 and NCRC-21 ELISAs (Table II) . 
Discussion
The Y haptenic blood group determinant is known to be expressed by malignant gastrointestinal cells (Brown et al., 1984; Lloyd et al., 1983; Abe et al., 1986) . This project shows that it is also released into the circulation in up to 33% of patients with extensive colorectal cancer.
RIA have previously been used in the detection of circulating tumour-associated antigens. The ELISA developed in this study presents many advantages over the RIA. Since no radioisotopes are used the ELISA is less hazardous and can be perfomred in any laboratory without the need for expensive gamma-counters. Radiolabelled antibody remains stable for only 1-2 months, whereas biotinylated antibody can be stored for an indefinite period. A large batch of antibody can be biotinylated and used in numerous assays, thereby allowing results to be reproducible. Brown et al. (1984) showed that the Y hapten was strongly expressed on the normal gastrointestinal epithelia of individuals of secretor status while being weak or absent in non-secretors. Of the normal individuals tested 11/13 were secretors but only one of these expressed Y hapten bearing antigens in the serum. It would appear that the antigen is not released generally into the circulation from normal gastrointestinal cells. All antigens detected by the assays in this study must carry a Y haptenic blood group determinant. There may, however, be several discrete antigens carrying this specific epitope. An Thirty-four per cent of colorectal cancer patients with extensive disease secreted an antigen recognised by two C14 molecules and 24% an antigen recognised by C14 and NCRC-21. This sensitivity is low compared to CEA (64%) but similar to that seen for secretion of CA 19-9 antigen (40%). However, there was no obvious correlation between expression of any of the antigens and in fact co-screening for all four antigens improved the sensitivity of recurrent cancer detection to 80%.
C14 shows a sensitivity of 67% for patients with recurrence and only a 30% sensitivity for patients with metastases, whereas CEA showed a similar sensitivity for both groups of patients and CA19-9 showed an elevated sensitivity in patients with overt hepatic metastases. This suggests that C14 could prove to be of clinical value in detecting recurrence that is potentially curable by second operations. This is particularly important in view of the fact that serum CEA levels are related to tumour bulk and therefore raised levels often occur when recurrence is beyond cure and liver metastases are present (Finlay & McArdle, 1983) . Despite a number of encouraging reports showing CEA to have a high sensitivity for recurrence (reviewed by Northover, 1986) , its late stage expression (Finlay & McArdle, 1983) and its high false negative rate of approximately 20% (Herrera et al., 1976; Wood et al., 1980) suggest its clinical value in detecting early recurrences is limited.
A further study including serum samples from a large age-matched normal panel, patients with inflammatory diseases, ademomatous polyps, primary cancer, recurrent disease and liver metastases is currently in progress. A prospective study to determine if this assay can detect recurrence earlier than other methods and hence improve treatment is also ongoing. However, these results are encouraging in view of the fact that no other tumour antigen has been reported to be expressed more by recurrent disease than by liver metastases. Antigens expressing the Y hapten may be useful in identifying patients with early potentially curable recurrent disease. 
